<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html>

<head>
    <title>Lilly</title>
    <meta http-equiv="content-type" content="text/html; charset=UTF-8">
    <link rel="stylesheet" type="text/css" href="fonts/stylesheet.css">
    <link rel="stylesheet" type="text/css" href="jquery.qtip.css">
    <link rel="stylesheet" type="text/css" href="site.css">
    <script src="http://ajax.googleapis.com/ajax/libs/jquery/1.6.1/jquery.min.js" type="text/javascript"></script>
    <script src="jquery.qtip-1.0.0-rc3-dm.js" type="text/javascript"></script>
    <script src="jquery.bpopup-0.5.1.min.js" type="text/javascript"></script>
    <script src="site.js" type="text/javascript"></script>
    <script type="text/javascript">
            $(document).ready(function() {
                // Match all <A/> links with a title tag and use it as the content (default).
                $('a.tooltip[title]').qtip({
                    position: {
                        adjust: {
                            x: 5,
                            y: 10
                        },
                        corner: {
                            target: 'topRight',
                            tooltip: 'topLeft'
                        }
                    },
                    style: {
                        width: 150,
                        name: 'dark',
                        tip: {
                            corner: 'topLeft',
                            color: '#979797',
                            size: {
                                x: 9,
                                y: 10
                            }
                        }
                    }
                });
                $('a.bigtooltip[title]').qtip({
                    position: {
                        adjust: {
                            x: 5,
                            y: 10
                        },
                        corner: {
                            target: 'topRight',
                            tooltip: 'topLeft'
                        }
                    },
                    style: {
                        width: 236,
                        name: 'dark',
                        tip: {
                            corner: 'topLeft',
                            color: '#979797',
                            size: {
                                x: 9,
                                y: 10
                            }
                        }
                    }
                });
                $('a.bigtooltip_left[title]').qtip({
                    position: {
                        adjust: {
                            x: 0,
                            y: 10
                        },
                        corner: {
                            target: 'topLeft',
                            tooltip: 'topRight'
                        }
                    },
                    style: {
                        width: 580,
                        name: 'dark',
                        tip: {
                            corner: 'topRight',
                            color: '#979797',
                            size: {
                                x: 9,
                                y: 10
                            }
                        }
                    }
                });

                /*
									$('a.tooltip_under[title]').qtip({
										position: {
											corner: {
												target: 'bottomCenter',
												tooltip: 'topCenter'
											}
										},
										style: {
											width: 96,
											name: 'gray'
										}
									});

									$('a.bigtooltip_under[title]').qtip({
										position: {
											corner: {
												target: 'bottomCenter',
												tooltip: 'topCenter'
											}
										},
										style: {
											width: 191,
											name: 'gray'
										}
									});
									$('.molecule-container li a label').each(function(){
										if($(this).html().length < 20){
											$(this).parent().css('padding-top', '3px');
											$(this).parent().css('line-height', '32px');
											$(this).parent().css('height', '32px');
										}
									});
									*/
            });
        </script>
</head>

<body>
    <div id="browser_notice">
        This website is optimized for visualization with Firefox and Internet Explorer (8 or 9)
    </div>
    <div id="container">
        <div id="header">
            <img src="./img/header.png" alt="Lilly - Development Pipeline" />
        </div>
        <div id="content">
            <div id="content-left">

                <h1 class="DINBold">
                    <a href="index.html">Pipeline Overview</a>
                </h1>

                <div class="menu">
                    <h2 class="DINBold">View by Therapeutic Area</h2>
                    <ul>
                        <li>
                            <a href="7.html" class="" title="Cardiovascular">Cardiovascular</a>
                        </li>
                        <li>
                            <a href="8.html" class="" title="Diabetes">Diabetes</a>
                        </li>
                        <li>
                            <a href="13.html" class="" title="Emerging Markets">Emerging Markets</a>
                        </li>
                        <li>
                            <a href="14.html" class="" title="Immunology">Immunology</a>
                        </li>
                        <li>
                            <a href="9.html" class="" title="Musculoskeletal">Musculoskeletal</a>
                        </li>
                        <li>
                            <a href="10.html" class="" title="Neuroscience">Neuroscience</a>
                        </li>
                        <li>
                            <a href="11.html" class="" title="Oncology">Oncology</a>
                        </li>
                    </ul>

                    <h2 class="DINBold">View by Molecule Type</h2>
                    <ul>
                        <li>
                            <a href="17.html" class="" title="Chemical entity (small)">Chemical entity (small)</a>
                        </li>
                        <li>
                            <a href="18.html" class="" title="Biologic entity (large)">Biologic entity (large)</a>
                        </li>
                    </ul>
                </div>

                <p>
                    <a class="bigtooltip" title="Date the pipeline website was last updated.">Pipeline movement since April 19, 2016</a>
                </p>
                <p>
                    <a class="bigtooltip" title="Information on the website is current as of this date. Changes to clinical development programs after this date are not reflected on the site.">Pipeline data through<br/>July 19, 2016</a>
                </p>

            </div>
            <div id="content-center-legend">
                <h1>UNDERSTANDING LILLY'S CLINICAL DEVELOPMENT
                    <span>PIPELINE</span> WEBSITE
                </h1>
                <div id="top_p">
                    <p>Thank you for visiting Lilly&rsquo;s Clinical Development Pipeline website. This interactive page is
                        designed to help you better understand the information contained on the site, particularly as it
                        relates to the molecules Lilly is currently developing for patients worldwide who are waiting. We
                        encourage you to click on the content on this page &ndash; including the dates on the left, the abbreviations
                        below and the terms in the legend to the right &ndash; for helpful definitions and background information.
                        Additionally, below are responses to some frequently asked questions regarding the site&rsquo;s information
                        and how it is displayed.&nbsp;</p>
                    <p class="MsoNormal">&nbsp;</p>
                    <p class="MsoNormal">We hope that after exploring this page, you find Lilly&rsquo;s Clinical Development Pipeline website
                        educational and easy to navigate.&nbsp;</p>
                </div>
                <div id="abbrev">
                    <h2>
                        <label class="exp"></label>
                        <span>Abbreviations<span></h2>
                                <div style="display: none;" class="legend-inner-content">
                                    <p>
                                        <strong>Disease-related</strong>
                                    </p>
                                    <ul>
                                        <li>
                                            <strong>ACS:</strong>
                                            acute coronary syndrome</li>
                                        <li>
                                            <strong>CKD:</strong>
                                            chronic kidney (renal) disease</li>
                                        <li>
                                            <strong>CV:</strong>
                                            cardiovascular</li>
                                        <li>
                                            <strong>DLBCL:</strong>
                                            diffuse large b-cell lymphoma</li>
                                        <li>
                                            <strong>EPI:</strong>
                                            exocrine pancreatic insufficiency</li>
                                        <li>
                                            <strong>NSCLC:</strong>
                                            non-small cell lung cancer</li>
                                        <li>
                                            <strong>RA:</strong>
                                            rheumatoid arthritis&nbsp;</li>
                                    </ul>
                                    <p><br/>
                                        <strong>Molecule-related</strong>
                                    </p>
                                    <ul>
                                        <li>
                                            <strong>Antag:</strong>
                                            antagonist</li>
                                        <li>
                                            <span style="font: bold 11pt serif;">&beta;</span>: beta</li>
                        <li>
                            <strong>Inh:</strong> inhibitor
                        </li>
                        <li>
                            <strong>MAb:</strong>&nbsp;monoclonal antibody</li>
                        <li>
                            <strong>Pept</strong>: peptide</li>
                        </ul>
                </div>
            </div>
            <div id="faq">
                <h2>
                    <label class="exp"></label>
                    <span>Frequently Asked Questions</span>
                </h2>
                <div style="display: none;" class="legend-inner-content">
                    <p>
                        <span class="question">
                                            <strong>What is the significance of the position of a molecule within a particular phase of development (Phase I, II, III or Regulatory Review) as compared to other molecules in that same phase?&nbsp;<br/></strong>
                                        </span>
                    </p>
                    <p>
                        <span class="answer">Molecules are grouped by therapeutic area, but there is no significance to a molecule&rsquo;s placement within a phase.
                                            <br/></span>
                    </p>
                    <p>&nbsp;</p>
                    <p>
                        <span class="question">
                                            <strong>What is the significance of the indications listed for each molecule?&nbsp;</strong>
                                        </span>
                    </p>
                    <p>
                        <span class="answer">For each molecule, the lead indication, or indication that is furthest along in clinical development, is listed in the molecule&rsquo;s &ldquo;box&rdquo; on the pipeline overview page. If a molecule is being studied for multiple indications,
                                            <em>select</em>
                                            additional indications will be listed in the molecule&rsquo;s full description, which is displayed once you click the molecule&rsquo;s box on the pipeline overview page.&nbsp;<br/><br/>For New Indication or Line Extension (NILEX) molecules, the indication listed is the lead indication undergoing clinical study and not the indication which is already approved by the U.S. Food and Drug Administration (FDA). &nbsp;</span>
                    </p>
                    <p>&nbsp;</p>
                    <p>
                        <span class="question">
                                            <strong>Why are some molecules not identified and simply referred to by therapeutic area (e.g., diabetes)?&nbsp;</strong>
                                        </span>
                    </p>
                    <p>
                        <span class="answer">For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.&nbsp;</span>
                    </p>
                    <p>&nbsp;</p>
                    <p>
                        <span class="question">
                                            <strong>How does Lilly determine when a molecule enters a particular phase of clinical development?&nbsp;</strong>
                                        </span>
                    </p>
                    <p>
                        <span class="answer">- Lilly considers Phase I clinical development to be underway once the first
                                            <strong>human</strong>
                                            dose has been given.<br/>- Lilly considers Phase II clinical development to be underway once the first
                                            <strong>efficacy</strong>
                                            dose has been given.<br/>- Lilly considers Phase III clinical development to be underway once the first
                                            <strong>registration</strong>
                                            dose has been given.<br/>- Lilly considers regulatory review to be underway when the first
                                            <strong>submission</strong>
                                            has been made.</span>
                    </p>
                    <p>&nbsp;</p>
                    <p>
                        <span class="question">
                                            <strong>What is a rolling FDA submission?</strong>
                                        </span>
                    </p>
                    <p>
                        <span class="answer">Unlike a standard FDA submission where all preclinical, clinical and manufacturing information for FDA review is submitted at once, a rolling submission allows a company to send individual pieces of information to the FDA as they
                                            are completed. As such, Lilly does not consider a molecule under "regulatory review" until all data has been submitted to the FDA.<br/><br/></span>&nbsp;</p>
                    <p>
                        <span class="question">
                                            <strong>How does Lilly define First Human Dose?</strong>
                                        </span>
                    </p>
                    <p>
                        <span class="answer">Lilly defines First Human Dose as the date of the first dose administered in the initial clinical study of the molecule given to healthy volunteers. This is typically a single dose pharmacokinetic safety study (study of how the
                                            investigational medicine acts on the body over a period of time, from a safety perspective). This dose may be active LY, placebo or comparator.&nbsp;<br/><br/>In some cases, like oncology and autoimmunity, the First Human Dose is given to patients with the disease the molecule is being studied to treat.</span>
                    </p>
                    <p>&nbsp;</p>
                    <p>
                        <span class="question">
                                            <strong>How does Lilly define&nbsp;First Efficacy Dose?</strong>
                                        </span>
                    </p>
                    <p>
                        <span class="answer">Lilly defines First Efficacy Dose as the date of the first dose administered to patients with the disease the molecule is being studied to treat, in a clinical study in which efficacy is a primary endpoint. The outcome of the
                                            clinical study should provide meaningful data on efficacy that drives a decision on whether or not to pursue development of the targeted indication for the molecule. This dose may be active LY, placebo or comparator. &nbsp;</span>
                    </p>
                    <p>&nbsp;</p>
                    <p>
                        <span class="question">
                                            <strong>How does Lilly define First Registration Dose?</strong>
                                        </span>
                    </p>
                    <p>
                        <span class="answer">Lilly defines First Registration Dose as the date of the first dose administered in the first large-scale pivotal study designed or intended to support registration in a major market (U.S., EU or Japan). This may occur before all
                                            Phase II studies have been completed. This dose may be active LY, placebo or comparator.&nbsp;</span>
                    </p>
                    <p>&nbsp;</p>
                    <p>
                        <span class="question">
                                            <strong>How does Lilly define First Submission?</strong>
                                        </span>
                    </p>
                    <p>
                        <span class="answer">Lilly defines First Submission as the initial submission of a regulatory dossier to a health authority to obtain regulatory approval for Lilly to market any indication or product form of a potential new medicine in one of the
                                            major markets (U.S., EU, China or Japan). &nbsp;</span>
                    </p>
                    <p>&nbsp;</p>
                    <p>
                        <span class="question">
                                            <strong>Which molecules include links to press releases and what is the criteria for press release inclusion?
                                            </strong>
                                        </span>
                    </p>
                    <p>
                        <span class="answer">For molecules in Phase III development, Lilly&rsquo;s interactive pipeline website includes links to press releases issued January 1, 2010 through October 16, 2014. Press releases from this timeframe are listed only if they focus
                                            solely on that specific molecule.<br/><br/>For announcements related to molecules in other phases (Phase I, Phase II, NILEX and regulatory review), as well as broader pipeline announcements or announcements dated before January 1, 2010, please visit the press release archives on the
                                            <a href="http://lilly.mediaroom.com/" target="_blank">Lilly.com News page</a>.</span>
                    </p>
                    <p>&nbsp;</p>
                    <p>
                        <span class="question">
                                            <strong>Why are some molecules listed on the pipeline website in Phase II clinical development, but noted as Phase I on ClinicalTrials.gov?</strong>
                                        </span>
                    </p>
                    <p>
                        <span class="answer">Lilly defines the start of Phase II as the first dose in a clinical study for the purpose of evaluating efficacy, whether that occurs in a Phase I cohort or a separate Phase II study. Some oncology pipeline molecules are
                                            considered by Lilly to be in Phase II clinical development, although ClinicalTrials.gov lists them as Phase I based on a Phase I study.</span>
                    </p>
                    <p>&nbsp;</p>
                    <p>
                        <span class="question">
                                            <strong>Why are only some of Lilly&rsquo;s Phase I studies listed on ClinicalTrials.gov?&nbsp;</strong>
                                        </span>
                    </p>
                    <p>
                        <span class="answer">Registry of a Phase I clinical study on ClinicalTrials.gov is not required by the FDA. Lilly began registering all Phase I clinical studies commencing on or after October 1, 2010 as part of a PhRMA commitment. Some Phase I
                                            studies were initiated prior to this time frame, and therefore are not registered on ClinicalTrials.gov.</span>
                    </p>
                    <p>&nbsp;</p>
                    <p>
                        <span class="question">
                                            <strong>Why are some molecules in the pipeline followed by a I or II?&nbsp;</strong>
                                        </span>
                    </p>
                    <p>
                        <span class="answer">In some cases, the pipeline includes two or more molecules that act on the same disease target. To distinguish these molecules until a nonproprietary name is granted, they are numbered on Lilly&rsquo;s pipeline website.&nbsp;</span>
                    </p>
                    <p>&nbsp;</p>
                    <p>
                        <span class="question">
                                            <strong>What is a commercial collaboration?&nbsp;</strong>
                                        </span>
                    </p>
                    <p>
                        <span class="answer">Some pipeline molecules will be commercialized (sold and marketed) with other companies after the medicine is approved. This is referred to as a commercial collaboration.<br/><br/>
                                            <strong>Commercial collaborations include:</strong><br/>- Empaglaflozin (from Boehringer Ingelheim)<br/>- New Insulin Glargine product (with Boehringer Ingelheim)</span>
                    </p>
                    <p>&nbsp;</p>
                    <p>
                        <span class="question">
                                            <strong>What is the difference between a chemical and biologic entity?</strong>
                                        </span>
                    </p>
                    <p>
                        <span class="answer">A new chemical entity is a molecule that is chemically derived, or synthesized through chemical processes. These are referred to as small molecules and are typically administered orally. A new biologic entity is comprised of
                                            biological products such as proteins, peptides or antibodies. These are referred to as large molecules and are typically administered intravenously.<br/></span>
                    </p>
                    <p>&nbsp;</p>
                </div>
            </div>

            <div class="disclaimer">
                <b>Pipeline Disclaimer</b><br/>The information included on this site reflects Eli Lilly and Company's clinical
                development pipeline and is not intended for promotional purposes. It includes both new molecular entities
                as well as select new indications or line extensions of currently-approved products, that are in clinical
                development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific
                and regulatory hurdles may cause pipeline molecules to be discontinued, delayed or fail to reach the market.
                There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove
                to be commercially successful. Information is current as of July 19, 2016. Lilly assumes no duty to update
                this information.
                <br><br> For competitive reasons, some pipeline molecules are not identified; in those instances, only the
                therapeutic area in which the molecule is being studied is listed.</div>
            <p class="footer">
                Property of Eli Lilly and Company.
            </p>
        </div>
        <div id="content-right">

            <div class="molecule-info2">
                <h1>Legend</h1>
                <div class="molecule-data"><img class="fl" align="absmiddle" src="./img/new_molecule.png" alt="" />
                    <div class="molecule-text">
                        <a class="bigtooltip_left" title="Indicates a molecule that has entered Lilly&#039;s clinical development pipeline through acquisition.">New Molecule</a>
                    </div>
                </div>
                <div class="molecule-data"><img class="fl" align="absmiddle" src="./img/achived_milestone_molecule.png" alt="" />
                    <div class="molecule-text">
                        <a class="bigtooltip_left" title="Indicates that a molecule has progressed from an earlier phase of clinical development into the next phase of development or has completed registration phase studies and has been submitted for regulatory review. ">Molecule That Achieved Milestone
                                        </a>
                    </div>
                </div>
                <div class="molecule-data"><img class="fl" align="absmiddle" src="./img/scientific_name_given.png" alt="" />
                    <div class="molecule-text">
                        <a class="bigtooltip_left" title="A nonproprietary name (also known as an established name or generic name) is a unique name for a molecule that follows naming conventions to reflect the characteristics of the molecule while distinguishing it from others that are available or in development. Nonproprietary names are proposed by the pharmaceutical company developing the molecule and recognized by official agencies (the United States Adopted Names Council, or USAN, in the U.S.) for general public use. The nonproprietary names are not subject to proprietary (trademark) rights like trade or brand names. &lt;br /&gt;&lt;br /&gt;A nonproprietary name may be granted at varying stages of clinical development and this timing does not have any significance in terms of the development status of the molecule. ">Nonproprietary Name Granted</a>
                    </div>
                </div>
                <div class="molecule-data"><img class="fl" align="absmiddle" src="./img/later_phase_molecule.png" alt="" />
                    <div class="molecule-text">
                        <a class="bigtooltip_left" title="">Molecule Moved to Earlier Phase</a>
                    </div>
                </div>
                <div class="molecule-data"><img class="fl" align="absmiddle" src="./img/lost_molecule.png" alt="" />
                    <div class="molecule-text">
                        <a class="bigtooltip_left" title="Indicates that a molecule is no longer in active clinical development. The molecule will be removed from Lillyâ€™s pipeline website at the next update. ">Lost Through Attrition</a>
                    </div>
                </div>
                <div class="molecule-data"><img class="fl" align="absmiddle" src="./img/checked.png" alt="" />
                    <div class="molecule-text">
                        <a class="bigtooltip_left" title="Indicates a molecule that has received regulatory approval in a major geography">Regulatory Approval Achieved</a>
                    </div>
                </div>
                <div class="molecule-data">
                    * Commercial Collaboration
                </div>
            </div>
            <ul class="molecule-info">
                <li>
                    <span class="nme_cell">
                                        <b>NME</b>
                                    </span>
                </li>

                <li>
                    <span class="nilex_cell">
                                        <b>Select NILEX</b>
                                    </span>
                </li>

                <li>
                    <span class="diagnostic_cell">
                                        <b>Diagnostic</b>
                                    </span>
                </li>
            </ul>
            <div id="full_legend_link" class="active">
                For more information about Lilly's interactive pipeline website,
                <a href="full_legend.html">click here</a>
            </div>
        </div>
    </div>
    <div id="footer"></div>
    </div>

    <script type="text/javascript">
                    $(window).load(function() {
                        var cCenterHeight = $('#content-center').height();
                        var cLeftHeight = $('#content-left').height();
                        var paddingTop = cCenterHeight - cLeftHeight - 10;
                        if (paddingTop > 0) {
                            //$('.footer').css('padding-top', parseInt(paddingTop)+'px');
                        }
                        $('.molecule-container').each(function() {

                            if (!$(this).has('li').length) {
                                $(this).css('padding', '0');
                            }

                            $(this).find('a.big').each(function() {

                                var a_height = $(this).height();

                                var label_height = $(this).find('label').height();
                                if (label_height != 0) {
                                    $(this).find('label').css('padding-top', parseInt(((a_height - label_height) / 2) - 5));
                                } else {
                                    $(this).find('label').css('padding-top', 12);
                                }
                            });

                        });
                        //Set default open/close settings $('.molecule-container').hide(); //Hide/close all containers $('.cells-container-inner h1:last').addClass('active').next().hide();

                    });
                </script>
    <script type="text/javascript">
                    $(document).ready(function() {
                        $('.answer').parent().hide();
                        $('#faq h2').toggleClass('active').next().slideDown(); //Add 'active' state to clicked trigger and slide down the immediate next container
                        $('#faq h2').children('label').toggleClass('exp_open');
                        $('span.question').first().parent('p').toggleClass('active');
                        $('span.question').first().parent('p').next('p').css('display', 'block');
                        //On Click
                        $('#abbrev h2, #faq h2').click(function() {
                            if ($(this).hasClass('active')) {
                                $(this).toggleClass('active').next().slideUp(); //Add 'active' state to clicked trigger and slide down the immediate next container
                                $(this).children('label').toggleClass('exp_open');
                            } else {
                                $(this).toggleClass('active').next().slideDown(); //Add 'active' state to clicked trigger and slide down the immediate next container
                                $(this).children('label').toggleClass('exp_open');
                            }
                            return false; //Prevent the browser jump to the link anchor
                        });

                        $('.question').css('cursor', 'pointer');
                        $('span.question').click(function() {
                            var question = $(this);
                            $('.answer').parent().each(function() {
                                if ($(this).prev('p').children('span.question').html() != question.html()) {
                                    $(this).hide();
                                    $(this).prev('p').removeClass('active');
                                }
                            });
                            if (question.parent().hasClass('active')) {
                                question.parent().nextAll().find('span.answer').eq(0).parent().hide();
                                question.parent().removeClass('active');
                            } else {
                                question.parent().nextAll().find('span.answer').eq(0).parent().show();
                                question.parent().addClass('active');
                            }

                        });
                    });
                </script>
    <!-- START OF SmartSource Data Collector TAG -->
    <!-- Copyright (c) 1996-2010 WebTrends Inc.  All rights reserved. -->
    <!-- Version: 9.3.0 -->
    <!-- Tag Builder Version: 3.1  -->
    <!-- Created: 2/10/2011 5:17:20 PM -->
    <script src="webtrends.js" type="text/javascript"></script>
    <!-- ----------------------------------------------------------------------------------- -->
    <!-- Warning: The two script blocks below must remain inline. Moving them to an external -->
    <!-- JavaScript include file can cause serious problems with cross-domain tracking.      -->
    <!-- ----------------------------------------------------------------------------------- -->
    <script type="text/javascript">
                    //<![CDATA[
                    var _tag = new WebTrends();
                    _tag.dcsGetId();

                    //]]>
                </script>
    <script type="text/javascript">
                    //<![CDATA[
                    _tag.dcsCustom = function() {
                        // Add custom parameters here. _tag.DCSext.param_name=param_value;
                    }
                    _tag.dcsCollect();

                    //]]>
                </script>
    <noscript>
        <div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="http://statse.webtrendslive.com/dcskykqjqvz5bd05pjea7z15r_7k3s/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.3.0&amp;WT.dcssip=www.lilly.com,lilly.com,elilly.com"
            /></div>
    </noscript>
    <!-- END OF SmartSource Data Collector TAG -->
</body>

</html>